News All of Ferrer’s information, just a click away Home News normal Apply Ferrer reports top-line results from Phase III ADORE study in ALS . Wed, 01/10/2024 - 10:52 Ferrer obtains the highest LEED certification rating for its Barcelona offices . Fri, 12/22/2023 - 10:59 More than 1,200 Ferrer volunteers unite in a global commitment to social justice for our Days for Good . Wed, 10/11/2023 - 16:25 The World Health Organization includes the cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines . Tue, 08/01/2023 - 10:58 We allocate, on average, more than 40% of our profits to social and environmental projects for the third consecutive year . Wed, 07/26/2023 - 10:13 Ferrer4Future launches its open innovation challenge to drive digital solutions for ALS . Fri, 06/23/2023 - 07:24 We extend our clinical study in amyotrophic lateral sclerosis (ALS) . Thu, 06/22/2023 - 06:30 We’ve been awarded EcoVadis GOLD Rating! . Thu, 03/30/2023 - 09:29 Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP) . Wed, 02/22/2023 - 09:30 We achieve Great Place To Work certification in 5 countries . Tue, 11/29/2022 - 18:17 Cargar más For requests for interviews or information, please contact the Communications Department CONTACT US alternatively, please dial +34 936 003 779 See more R&D Strategy Business Development
Ferrer obtains the highest LEED certification rating for its Barcelona offices . Fri, 12/22/2023 - 10:59
More than 1,200 Ferrer volunteers unite in a global commitment to social justice for our Days for Good . Wed, 10/11/2023 - 16:25
The World Health Organization includes the cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines . Tue, 08/01/2023 - 10:58
We allocate, on average, more than 40% of our profits to social and environmental projects for the third consecutive year . Wed, 07/26/2023 - 10:13
Ferrer4Future launches its open innovation challenge to drive digital solutions for ALS . Fri, 06/23/2023 - 07:24
Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP) . Wed, 02/22/2023 - 09:30